| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
Vinyl myristate does not have a defined primary pharmacological target as it is primarily a chemical reagent and synthetic intermediate. In biomedical research, the compound serves as a building block for synthesizing polymers and other materials. The vinyl ester functionality allows for polymerization reactions to produce materials with potential applications in drug delivery, tissue engineering, and other biomedical fields. The myristate moiety, derived from myristic acid, is a fatty acid chain that can interact with lipid membranes and may be incorporated into lipid-based drug delivery systems. The compound's primary utility is in materials science rather than as a direct pharmacological agent.
|
|---|---|
| ln Vitro |
In vitro activity of vinyl myristate as a standalone compound is not typically evaluated, as its primary role is as a chemical reagent and polymer precursor. The compound's biological activity would be assessed through the materials or drug delivery systems synthesized from this building block. In biochemical research, vinyl myristate may be used in the preparation of polymer-based biomaterials for cell culture or tissue engineering applications. The myristate moiety may contribute to membrane interactions when incorporated into materials, potentially affecting cell adhesion, proliferation, or differentiation. However, specific in vitro activity data for the compound itself are not available.
|
| ln Vivo |
In vivo activity data for vinyl myristate are not available, as the compound is not intended for direct administration as a therapeutic agent. It is classified as a biochemical reagent and chemical intermediate. Any in vivo effects would be associated with the materials or drug delivery systems synthesized from this compound rather than the compound itself. The compound's role in biomedical research is to enable the synthesis of polymers and other materials that may be evaluated in animal models for applications such as drug delivery, tissue engineering, or medical devices. Researchers handling this compound should follow appropriate safety protocols.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for vinyl myristate are not standard, as the compound is a chemical reagent rather than a drug candidate. If evaluated, typical assays might involve studying the compound's interactions with lipid membranes or its potential as a substrate for esterases. For esterase activity studies, the compound could be incubated with purified esterases or lipases in appropriate buffer systems, with hydrolysis monitored by chromatographic methods. However, such studies are not commonly performed on this compound, as its primary applications are in materials science rather than pharmacology.
|
| Cell Assay |
Cell-based in vitro experiments using vinyl myristate are not typically performed, as the compound is a research chemical and polymer precursor. When used in cell biology research, the compound might be incorporated into polymer-based materials that are then tested on cultured cell lines. Standard cell culture protocols would involve seeding cells in appropriate media at 37°C in a 5% CO₂ atmosphere, exposing cells to materials containing vinyl myristate-derived polymers, and assessing cell viability, proliferation, or other endpoints using standard assays. The compound's potential cytotoxicity and solvent compatibility should be considered.
|
| Animal Protocol |
In vivo animal studies are not conducted with vinyl myristate itself, as it is a chemical reagent rather than a therapeutic agent. The compound is utilized in the synthesis of polymers and materials that may subsequently be evaluated in animal models for biomedical applications. For drug delivery applications, typical in vivo protocols would involve administration of polymer-based formulations via various routes (oral, subcutaneous, intravenous) to rodents, with assessment of drug release, pharmacokinetics, and therapeutic efficacy. For tissue engineering applications, implanted materials would be evaluated for biocompatibility and tissue integration. All animal studies must be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of vinyl myristate have not been characterized, as the compound is a chemical reagent for research use. As a fatty acid ester with molecular weight 254.41 g/mol, the compound would be expected to be highly lipophilic with low aqueous solubility. The vinyl ester would be susceptible to hydrolysis by esterases, yielding myristic acid and acetaldehyde. Myristic acid would be absorbed and metabolized through fatty acid oxidation pathways. However, these properties are not studied for the compound itself, as it is not developed as a pharmaceutical. The compound is typically stabilized with MEHQ to prevent polymerization, which may also affect its handling and stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for vinyl myristate are limited, as the compound is handled as a research chemical in laboratory environments. Standard safety precautions should be followed, including the use of appropriate personal protective equipment such as gloves, goggles, and lab coats. The compound may cause irritation to skin, eyes, and respiratory tract upon exposure. Inhalation of vapor should be avoided, and adequate ventilation should be ensured. The MEHQ stabilizer may contribute to the compound's toxicity profile. In case of contact, affected areas should be rinsed with plenty of water. The compound should be stored in a cool, dry place away from light and oxidizing agents. Comprehensive toxicological studies have not been reported.
|
| Additional Infomation |
Vinyl myristate is a chemical research tool and synthetic intermediate rather than an approved pharmaceutical drug. Its primary applications are in polymer chemistry and materials science, where it serves as a vinyl ester monomer for polymerization reactions. The compound is also used as a biochemical reagent for biomedical research. The myristate moiety, derived from myristic acid found in coconut oil and palm kernel oil, provides lipophilic properties that may be useful in the design of lipid-based materials and drug delivery systems. No clinical trials or regulatory approvals have been documented for this compound as a therapeutic agent. The compound is commercially available as a research-grade chemical, supplied for laboratory synthesis and materials research.
|
| Molecular Formula |
C16H30O2
|
|---|---|
| Molecular Weight |
254.41
|
| Exact Mass |
254.225
|
| CAS # |
5809-91-6
|
| PubChem CID |
545633
|
| Appearance |
Colorless to off-white Solid-Liquid Mixture
|
| Density |
0.87
|
| Boiling Point |
148ºC / 4.8mmHg
|
| Flash Point |
148ºC
|
| Index of Refraction |
1.446
|
| LogP |
5.374
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
18
|
| Complexity |
199
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC(=O)OC=C
|
| InChi Key |
ZQZUENMXBZVXIZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H30O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16(17)18-4-2/h4H,2-3,5-15H2,1H3
|
| Chemical Name |
ethenyl tetradecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9307 mL | 19.6533 mL | 39.3066 mL | |
| 5 mM | 0.7861 mL | 3.9307 mL | 7.8613 mL | |
| 10 mM | 0.3931 mL | 1.9653 mL | 3.9307 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
